Value in Oncology, an Interview with Marty Neltner

Podcast

In this exclusive CancerNetwork Blog podcast, nationally regarded healthcare specialist, Marty Neltner, talks about, among other things, how to bring value into an oncology practice.

Marty Neltner

Marty Neltner

In this exclusive Cancer Network podcast, nationally regarded healthcare specialist, Marty Neltner, talks about, among other things, how to bring value into an oncology practice.

Given the current atmosphere in today's challenging healthcare market, community oncology practices need to be especially alert to future trends, one of which is value over volume. In oncology's world, that translates into value over chemo reimbursement.

-Interviewed by Ron Piana

Recent Videos
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Earlier and more frequent talks about disabling ICDs with patients receiving end-of-life care and their families may help avoid excessive pain.
3 experts in this video
3 experts in this video
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
Related Content
Developments in CAR T-Cell and Bispecific Therapies in R/R Multiple Myeloma

Developments in CAR T-Cell and Bispecific Therapies in R/R Multiple Myeloma

ONCOLOGY Staff
February 22nd 2025
Article

Hematology oncology experts discuss recent developments in CAR T-cell therapies as well as bispecific therapies for the treatment of patients with R/R MM.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Highlighting Insights From the Marginal Zone Lymphoma Workshop

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD
February 17th 2025
Podcast

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Tambiciclib/Zanubrutinib Yields Promising Responses in R/R DLBCL

Tambiciclib/Zanubrutinib Yields Promising Responses in R/R DLBCL

Tim Cortese
February 21st 2025
Article

Tambiciclib plus zanubrutinib doubled the expected ORR of zanubrutinib monotherapy, eliciting an ORR of 67% in patients with relapsed or refractory DLBCL.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Navigating Management and Dosing Considerations for Amivantamab in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
February 10th 2025
Podcast

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Understanding patient preferences for intensive end-of-life treatment may better inform research assessing patients with terminal cancer diagnoses.

Improving End-of-Life Care in ICD Users With Advanced Cancers

Megan Mullins, PhD, MPH
February 20th 2025
Article

Understanding patient preferences for intensive end-of-life treatment may better inform research assessing patients with terminal cancer diagnoses.

Results from the phase 1/2a SeCuRE trial support the FDA decision for patients with metastatic castration-resistant prostate cancer.

Cu-67 SAR-bisPSMA Granted Fast Track Designation for Metastatic CRPC

Roman Fabbricatore
February 20th 2025
Article

Results from the phase 1/2a SeCuRE trial support the FDA decision for patients with metastatic castration-resistant prostate cancer.